Merck announced an extensive cost reduction program aimed at saving $3 billion annually by 2027 to offset declining sales of Gardasil and upcoming patent expiration of Keytruda. The multiyear initiative includes workforce reductions in administrative, sales, and R&D functions, as well as shrinking its global real estate and optimizing manufacturing operations. Savings will be reinvested in new product launches and pipeline development. Keytruda's sales reached $8 billion in Q2, accounting for over half of Merck’s total revenue, underlining the company's dependence on the immuno-oncology blockbuster.